

# Pieter Evenepoel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2776557/publications.pdf>

Version: 2024-02-01

292  
papers

16,185  
citations

11608

70  
h-index

20900

115  
g-index

297  
all docs

297  
docs citations

297  
times ranked

12200  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, progression and implications of breast artery calcification in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 295-302.	1.4	6
2	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. American Journal of Kidney Diseases, 2022, 79, 667-676.e1.	2.1	25
3	Natural History of Bone Disease following Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 638-652.	3.0	12
4	Contemporary kidney transplantation has a limited impact on bone microarchitecture. Bone Reports, 2022, 16, 101172.	0.2	2
5	Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence. Toxins, 2022, 14, 210.	1.5	5
6	Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3532-e3533.	1.8	3
7	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients, 2022, 14, 1742.	1.7	8
8	MO587: Chronic Kidney Disease Induces Endotoxin-Related Activation of The Innate Immune System. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
9	Bone histomorphometry for the diagnosis of renal osteodystrophy: a call for harmonization of reference ranges. Kidney International, 2022, 102, 431-434.	2.6	5
10	Clinical utility of bone turnover markers in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 332-338.	1.0	6
11	Lipid Profile Is Negatively Associated with Uremic Toxins in Patients with Kidney Failure—A Tri-National Cohort. Toxins, 2022, 14, 412.	1.5	5
12	Bone health in ageing men. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 1173-1208.	2.6	8
13	Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease. Bone, 2022, 162, 116482.	1.4	8
14	Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 413-425.	0.4	30
15	European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4—G5D. Nephrology Dialysis Transplantation, 2021, 36, 42-59.	0.4	107
16	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrology Dialysis Transplantation, 2021, 36, 160-169.	0.4	19
17	Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. Journal of Endocrinological Investigation, 2021, 44, 1437-1446.	1.8	14
18	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nature Reviews Nephrology, 2021, 17, 153-171.	4.1	126

#	ARTICLE	IF	CITATIONS
19	Vitamin K in CKD Bone Disorders. <i>Calcified Tissue International</i> , 2021, 108, 476-485.	1.5	15
20	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0247623.	1.1	14
21	Traditional and Non-traditional Risk Factors for Osteoporosis in CKD. <i>Calcified Tissue International</i> , 2021, 108, 496-511.	1.5	20
22	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	1.3	47
23	FC 076DIAGNOSTIC ACCURACY OF BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
24	MO455LIPID PROFILE AND UREMIC RETENTION SOLUTES IN PATIENTS WITH END-STAGE KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
25	Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. <i>Kidney International</i> , 2021, 99, 1173-1178.	2.6	11
26	FC 124PATTERNS OF RENAL OSTEODYSTROPHY ONE YEAR AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
27	MO568STATIC PARAMETERS OF HISTOMORPHOMETRY FOR THE EVALUATION OF BONE TURNOVER IN RENAL OSTEODYSTROPHY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
28	MO524CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
29	MO792CONTEMPORARY MINERAL AND BONE DISORDER MARKERS AND TREATMENT AMONG HEMODIALYSIS PATIENTS IN THE EUROPEAN DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
30	European hemodialysis patient satisfaction with phosphate binders is associated with serum phosphorus levels: the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1886-1893.	1.4	1
31	Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. <i>Osteoporosis International</i> , 2021, 32, 2397-2405.	1.3	18
32	Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 855-865.	2.9	18
33	Patterns of renal osteodystrophy 1â€™year after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2130-2139.	0.4	11
34	Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study. , 2021, 31, 512-522.		29
35	Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. <i>Kidney International</i> , 2021, 100, 546-558.	2.6	39
36	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. <i>Bone</i> , 2021, 152, 116066.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Hepatic and Vascular Vitamin K Status in Patients with High Cardiovascular Risk. <i>Nutrients</i> , 2021, 13, 3490.	1.7	6
38	<i>AQP1</i> Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 1570-1580.	13.9	34
39	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1901-1907.	1.4	10
40	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 697-705.	0.4	21
41	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 906-908.	1.4	1
42	Bone biomarkers in de novo renal transplant recipients. <i>Clinica Chimica Acta</i> , 2020, 501, 179-185.	0.5	9
43	Uremic Toxins and Vascular Calcification—Missing the Forest for All the Trees. <i>Toxins</i> , 2020, 12, 624.	1.5	14
44	Clinical evidence of direct bone effects of cinacalcet. <i>Kidney International</i> , 2020, 98, 514-515.	2.6	4
45	Therapy-Resistant Hypercalcemia in a Patient with Inactivating CYP24A1 Mutation and Recurrent Nephrolithiasis: Beware of Concomitant Hyperparathyroidism. <i>Calcified Tissue International</i> , 2020, 107, 524-528.	1.5	6
46	P1064HEPARIN-FREE DIALYSIS: A PHASE II PILOT STUDY USING ASYMMETRIC TRIACETATE (ATA) CELLULOSE DIALYZERS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
47	P1388ASSESSING BONE TURNOVER IN CHRONIC KIDNEY DISEASE: SHOULD WE MEASURE NON-OXIDIZED PTH. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
48	Spot urine versus 24-hour urine collection for estimation of the generation of uremic toxins originating from gut microbial metabolism. <i>Kidney International</i> , 2020, 98, 782-784.	2.6	1
49	Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study. <i>European Journal of Endocrinology</i> , 2020, 183, 181-189.	1.9	6
50	Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. <i>Bone</i> , 2020, 138, 115460.	1.4	14
51	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug—Bug Interaction?. <i>Toxins</i> , 2020, 12, 351.	1.5	14
52	Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1794-1801.	0.4	37
53	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. <i>Kidney International Reports</i> , 2020, 5, 627-631.	0.4	13
54	A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy. <i>JBMR Plus</i> , 2020, 4, e10353.	1.3	12

#	ARTICLE	IF	CITATIONS
55	The Role of Gut Dysbiosis in the Bone-Vascular Axis in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 285.	1.5	23
56	Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. <i>Scientific Reports</i> , 2020, 10, 6586.	1.6	53
57	PTH Receptors and Skeletal Resistance to PTH Action. , 2020, , 51-77.		2
58	Sclerostin in chronic kidney disease—mineral bone disorder think first before you block it!. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 408-414.	0.4	46
59	Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. <i>Kidney International Reports</i> , 2019, 4, 987-994.	0.4	12
60	Reply to: Poor Vitamin K Status in Chronic Kidney Disease: An Indirect Indicator of Hip Fragility. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1544-1545.	3.1	0
61	A distinct bone phenotype in ADPKD patients with end-stage renal disease. <i>Kidney International</i> , 2019, 95, 412-419.	2.6	23
62	Intestinal microbiome and fitness in kidney disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 531-545.	4.1	140
63	The Bone after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 795-797.	2.2	10
64	Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. <i>Kidney International</i> , 2019, 95, 1461-1470.	2.6	61
65	Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 751-766.	3.0	122
66	Bone-Vascular Axis in Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 472-483.	0.6	53
67	Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 2027.	1.0	15
68	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	1.4	29
69	Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 262-269.	3.1	51
70	Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. <i>Pharmacological Research</i> , 2018, 133, 101-107.	3.1	38
71	Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1404-1410.	0.4	22
72	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 319-331.	5.5	102

#	ARTICLE	IF	CITATIONS
73	Sclerostin deficiency modifies the development of CKD-MBD in mice. <i>Bone</i> , 2018, 107, 115-123.	1.4	20
74	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—“Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. <i>Annals of Internal Medicine</i> , 2018, 168, 422.	2.0	228
75	SuO003INDOXYL SULFATE AND P-CRESYL SULFATE PROMOTE VASCULAR CALCIFICATION BY GLUCOSE MEDIATED ACTIVATION OF INFLAMMATION AND COAGULATION PATHWAYS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i617-i617.	0.4	0
76	Facing cinacalcet-induced hypocalcemia: sit back and relax?. <i>Kidney International</i> , 2018, 93, 1275-1277.	2.6	12
77	Intestinal Barrier Function in Chronic Kidney Disease. <i>Toxins</i> , 2018, 10, 298.	1.5	78
78	Variations of sclerostin with other bone biomarkers over a one-year period in hemodialysis patients. <i>Clinica Chimica Acta</i> , 2018, 486, 183-184.	0.5	1
79	Clinical case report: a rare cause of acute kidney failure — tissue is the issue. <i>Acta Clinica Belgica</i> , 2017, 72, 201-204.	0.5	3
80	Sclerostin—A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. <i>Kidney International Reports</i> , 2017, 2, 481-485.	0.4	6
81	1 <sup>2</sup> ,25-Dihydroxyvitamin D 3 : A new vitamin D metabolite in human serum. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 173, 341-348.	1.2	18
82	Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1608-1613.	0.4	41
83	Biomarkers Predicting Bone Turnover in the Setting of CKD. <i>Current Osteoporosis Reports</i> , 2017, 15, 178-186.	1.5	34
84	A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CITED study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 707-714.	0.4	20
85	Executive summary of the 2017 KDIGO Chronic Kidney Disease—“Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. <i>Kidney International</i> , 2017, 92, 26-36.	2.6	698
86	Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD?. <i>Kidney International</i> , 2017, 91, 11-13.	2.6	4
87	Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. <i>Kidney International</i> , 2017, 91, 469-476.	2.6	40
88	Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4210-4217.	1.8	15
89	Update on the role of bone biopsy in the management of patients with CKD—“MBD. <i>Journal of Nephrology</i> , 2017, 30, 645-652.	0.9	31
90	p -cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky. <i>Kidney International</i> , 2017, 92, 1323-1324.	2.6	22

#	ARTICLE	IF	CITATIONS
91	The gut-kidney axis. <i>Pediatric Nephrology</i> , 2017, 32, 2005-2014.	0.9	188
92	Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. <i>PLoS ONE</i> , 2017, 12, e0176411.	1.1	37
93	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2016, 11, e0153893.	1.1	74
94	Oxidative Stress in Chronic Kidney Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-2.	1.9	30
95	A liquid chromatography tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. <i>Analytica Chimica Acta</i> , 2016, 936, 149-156.	2.6	40
96	Magnesium-based interventions for normal kidney function and chronic kidney disease. <i>Magnesium Research</i> , 2016, 29, 126-140.	0.4	18
97	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>Transplantation</i> , 2016, 100, 2188-2193.	0.5	21
98	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. <i>EBioMedicine</i> , 2016, 4, 162-169.	2.7	44
99	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3479-3487.	3.0	144
100	Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1136-1144.	2.2	57
101	Mineral metabolism disturbances in kidney donors: smoke, no fire (yet). <i>Kidney International</i> , 2016, 90, 734-736.	2.6	1
102	Parathyroid hormone metabolism and signaling in health and chronic kidney disease. <i>Kidney International</i> , 2016, 90, 1184-1190.	2.6	123
103	Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 867.	2.6	7
104	The Case   Hypercalcemia in a child with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 233-234.	2.6	2
105	Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?. <i>Kidney International</i> , 2016, 89, 21-23.	2.6	7
106	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1211-1219.	0.4	52
107	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1508-1514.	0.4	32
108	The influence of renal transplantation on retained microbial-human co-metabolites. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1721-1729.	0.4	35

#	ARTICLE	IF	CITATIONS
109	Inflammation and the bone-vascular axis in end-stage renal disease. <i>Osteoporosis International</i> , 2016, 27, 489-497.	1.3	33
110	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. <i>American Journal of Kidney Diseases</i> , 2016, 67, 483-498.	2.1	271
111	The Influence of CKD on Colonic Microbial Metabolism. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1389-1399.	3.0	106
112	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 281-292.	3.0	65
113	From skeletal to cardiovascular disease in 12 steps – the evolution of sclerostin as a major player in CKD-MBD. <i>Pediatric Nephrology</i> , 2016, 31, 195-206.	0.9	51
114	Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. <i>Discoveries</i> , 2016, 4, e55.	1.5	13
115	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. <i>American Journal of Transplantation</i> , 2015, 15, 2900-2907.	2.6	43
116	Microscopic nephrocalcinosis in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 843-848.	0.4	17
117	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 567-571.	1.4	12
118	The fate of triaged and rejected manuscripts. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1947-1950.	0.4	9
119	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	2.9	38
120	Pro: Cardiovascular calcifications are clinically relevant. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 345-351.	0.4	53
121	Sclerostin and DKK1: new players in renal bone and vascular disease. <i>Kidney International</i> , 2015, 88, 235-240.	2.6	118
122	The metabolomics grail: promising although not yet holy. <i>Kidney International</i> , 2015, 87, 864.	2.6	1
123	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 698-700.	0.4	23
124	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 357-357.	0.4	6
125	Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4669-4676.	1.8	53
126	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. <i>Kidney International</i> , 2015, 87, 210-216.	2.6	52

#	ARTICLE	IF	CITATIONS
127	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1525-1533.	2.2	59
128	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 288-293.	0.4	111
129	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. <i>PLoS ONE</i> , 2015, 10, e0140820.	1.1	77
130	Heritability and Clinical Determinants of Serum Indoxyl Sulfate and p-Cresyl Sulfate, Candidate Biomarkers of the Human Microbiome Enterotype. <i>PLoS ONE</i> , 2014, 9, e79682.	1.1	28
131	The Clinical Features of Trombotic Microangiopathies Post Transplantation.. <i>Transplantation</i> , 2014, 98, 532.	0.5	0
132	Proteinuria, Histology and Kidney-Allograft Survival.. <i>Transplantation</i> , 2014, 98, 78-79.	0.5	0
133	Heparin-coated dialyzer membranes: is non-inferiority good enough?. <i>Kidney International</i> , 2014, 86, 1084-1086.	2.6	18
134	Serum Concentrations of p-Cresyl Sulfate and Indoxyl Sulfate, But Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function. <i>Peritoneal Dialysis International</i> , 2014, 34, 71-78.	1.1	34
135	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. <i>Kidney International</i> , 2014, 86, 1001-1006.	2.6	13
136	A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>American Journal of Transplantation</i> , 2014, 14, 2545-2555.	2.6	77
137	Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 577.	0.6	0
138	The Histology of Kidney Transplant Failure. <i>Transplantation</i> , 2014, 98, 427-435.	0.5	124
139	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. <i>Kidney International</i> , 2014, 85, 636-640.	2.6	106
140	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1965-1972.	0.4	10
141	Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?. <i>Seminars in Nephrology</i> , 2014, 34, 151-163.	0.6	62
142	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. <i>Kidney International</i> , 2013, 83, 789-791.	2.6	21
143	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. <i>Transplant International</i> , 2013, 26, 973-981.	0.8	36
144	Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 165-175.	1.1	104

#	ARTICLE	IF	CITATIONS
145	The Colon: An Overlooked Site for Therapeutics in Dialysis Patients. <i>Seminars in Dialysis</i> , 2013, 26, 323-332.	0.7	71
146	Safety Issues Related to Fractionated Plasma Separation, Adsorption, and Dialysis. <i>Artificial Organs</i> , 2013, 37, 743-744.	1.0	0
147	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. <i>American Journal of Transplantation</i> , 2013, 13, 1910-1914.	2.6	19
148	Renal safety in patients treated with bisphosphonates for osteoporosis: A review. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2049-2059.	3.1	91
149	Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients. <i>Seminars in Nephrology</i> , 2013, 33, 191-203.	0.6	81
150	Sclerostin: Another Vascular Calcification Inhibitor?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3221-3228.	1.8	143
151	Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3024-3030.	0.4	105
152	Intrarenal Resistive Index after Renal Transplantation. <i>New England Journal of Medicine</i> , 2013, 369, 1797-1806.	13.9	185
153	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. <i>Acta Clinica Belgica</i> , 2013, 68, 215-217.	0.5	2
154	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1508-1514.	2.2	93
155	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. <i>Transplant International</i> , 2013, 26, 813-821.	0.8	51
156	Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparin-Induced Thrombocytopenia: Dose-Finding Study and Safety Evaluation. <i>Artificial Organs</i> , 2013, 37, 482-487.	1.0	21
157	Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2017-2022.	0.4	36
158	Calcium balance in chronic kidney disease: walking the tightrope. <i>Kidney International</i> , 2012, 81, 1057-1059.	2.6	8
159	Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial. <i>British Journal of Nutrition</i> , 2012, 108, 2229-2242.	1.2	106
160	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. <i>American Journal of Nephrology</i> , 2012, 35, 24-30.	1.4	13
161	Evidence in Favor of a Severely Impaired Net Intestinal Calcium Absorption in Patients with (Early-Stage) Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2012, 35, 434-441.	1.4	17
162	Uremia Suppresses Immune Signal-Induced CYP27B1 Expression in Human Monocytes. <i>American Journal of Nephrology</i> , 2012, 36, 497-508.	1.4	34

#	ARTICLE	IF	CITATIONS
163	Daytime Rhythm and Treatment-Related Fluctuations of Serum Phosphorus Concentration in Dialysis Patients. <i>American Journal of Nephrology</i> , 2012, 35, 242-248.	1.4	16
164	Mineral and bone disease - CKD 1-5. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, ii146-ii158.	0.4	0
165	Transplantation - clinical I. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, ii304-ii316.	0.4	2
166	Cardiovascular complications in CKD 5D. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, ii227-ii251.	0.4	0
167	Bone and mineral diseases - 1. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, ii36-ii37.	0.4	0
168	Recipients' Smoking Habits and Death-Censored Renal Allograft Survival. <i>Transplantation</i> , 2012, 94, 24.	0.5	0
169	Phosphate binder therapy "cracks in the tower of strength?". <i>Nature Reviews Nephrology</i> , 2012, 8, 615-616.	4.1	4
170	Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. <i>Kidney International</i> , 2012, 81, 227-229.	2.6	41
171	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating System-Based Liver Dialysis. <i>Artificial Organs</i> , 2012, 36, 29-41.	1.0	9
172	Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient. <i>Transplant International</i> , 2012, 25, e27-e28.	0.8	3
173	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. <i>Clinical Transplantation</i> , 2012, 26, 393-402.	0.8	36
174	Prevalence and determinants of anemia in the immediate postkidney transplant period. <i>Transplant International</i> , 2011, 24, 1208-1215.	0.8	19
175	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. <i>American Journal of Nephrology</i> , 2011, 34, 226-232.	1.4	22
176	The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 759-761.	0.4	203
177	Warning: the unfortunate end of p-cresol as a uraemic toxin. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1464-1467.	0.4	86
178	Calcium metabolism in the early post-transplant period. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2011, 63, 89-99.	3.9	1
179	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. <i>Transplantation</i> , 2010, 89, 341-346.	0.5	11
180	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. <i>Transplantation</i> , 2010, 89, 1296-1297.	0.5	6

#	ARTICLE	IF	CITATIONS
181	Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1887-1892.	2.2	36
182	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1268-1276.	2.2	96
183	p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 219-224.	0.4	260
184	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2672-2679.	0.4	77
185	Targeting hyperphosphatemia: truth or dare. <i>Kidney International</i> , 2010, 77, 256-257.	2.6	1
186	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2085-2092.	2.2	23
187	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1182-1189.	2.2	265
188	Quantification of <sup>15</sup> N-Nitrate in Urine with Gas Chromatography Combustion Isotope Ratio Mass Spectrometry to Estimate Endogenous NO Production. <i>Analytical Chemistry</i> , 2010, 82, 601-607.	3.2	10
189	Coagulation and Fractionated Plasma Separation and Adsorption. <i>American Journal of Transplantation</i> , 2009, 9, 242-243.	2.6	3
190	p-Cresyl Sulfate and Indoxyl Sulfate in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1932-1938.	2.2	142
191	Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3886-3890.	0.4	6
192	Uremic toxins originating from colonic microbial metabolism. <i>Kidney International</i> , 2009, 76, S12-S19.	2.6	349
193	Simultaneous Control of PTH and Ca <sup>2+</sup> -P Is Sustained over Three Years of Treatment with Cinacalcet HCl. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1465-1476.	2.2	29
194	Calcium Metabolism in the Early Posttransplantation Period. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 665-672.	2.2	72
195	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. <i>American Journal of Transplantation</i> , 2009, 9, 2470-2478.	2.6	46
196	Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial. <i>American Journal of Kidney Diseases</i> , 2009, 54, 77-85.	2.1	63
197	The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage. <i>American Journal of Kidney Diseases</i> , 2009, 54, 891-901.	2.1	219
198	Opinion: When is Vitamin D Contraindicated in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2009, 22, 242-244.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. <i>Journal of Chromatography A</i> , 2009, 1216, 4684-4688.	1.8	65
200	Removal of the Uremic Retention Solute (p-cresol) Using Fractionated Plasma Separation and Adsorption. <i>Artificial Organs</i> , 2008, 32, 214-219.	1.0	60
201	A Review of Albumin Binding in CKD. <i>American Journal of Kidney Diseases</i> , 2008, 51, 839-850.	2.1	99
202	Influenza Vaccination Is Efficacious and Safe in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2008, 8, 332-337.	2.6	139
203	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. <i>Nephron Clinical Practice</i> , 2008, 110, c80-c85.	2.3	51
204	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 417-419.	1.3	29
205	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2033-2042.	0.4	65
206	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. <i>Kidney International</i> , 2008, 74, 265-275.	2.6	40
207	Recovery of Hyperphosphatemia and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1829-1836.	2.2	124
208	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 278-285.	0.4	70
209	Free p-cresol is associated with cardiovascular disease in hemodialysis patients. <i>Kidney International</i> , 2008, 73, 1174-1180.	2.6	276
210	Living donor kidney transplantation: analysis of the first 40 cases performed in UZ Leuven. <i>Acta Chirurgica Belgica</i> , 2008, 108, 39-44.	0.2	0
211	Control of hyperphosphatemia beyond phosphate. <i>Kidney International</i> , 2007, 71, 376-379.	2.6	12
212	Parathyroidectomy after successful kidney transplantation: a single centre study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1730-1737.	0.4	96
213	Response to "Superior dialytic clearance of $\beta_2$ -microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis". <i>Kidney International</i> , 2007, 71, 467-468.	2.6	1
214	Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. <i>Transplant International</i> , 2007, 20, 381-385.	0.8	24
215	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. <i>British Journal of Dermatology</i> , 2007, 158, 071018053044006-???	1.4	29
216	Tertiary Hyperphosphatemia Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 1193-1200.	2.6	143

#	ARTICLE	IF	CITATIONS
217	Major Coagulation Disturbances During Fractionated Plasma Separation and Adsorption. American Journal of Transplantation, 2007, 7, 2195-2199.	2.6	65
218	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. American Journal of Kidney Diseases, 2007, 49, 642-649.	2.1	68
219	Late Referral of Patients With Chronic Kidney Disease: No Time to Waste. Mayo Clinic Proceedings, 2006, 81, 1487-1494.	1.4	50
220	The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon. British Journal of Nutrition, 2006, 96, 1078-1086.	1.2	53
221	Effect of MARS and PROMETHEUS on systemic hemodynamics and vasoactive agents in patients with acute on-chronic alcoholic liver failure: the clash of the titans. European Journal of Gastroenterology and Hepatology, 2006, 18, A38.	0.8	2
222	Clinically Relevant Drug Interaction Between Voriconazole and Tacrolimus in a Primary Renal Allograft Recipient. Transplantation, 2006, 81, 1750-1752.	0.5	21
223	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. Artificial Organs, 2006, 30, 276-284.	1.0	105
224	Review article: non-biological liver support in liver failure. Alimentary Pharmacology and Therapeutics, 2006, 23, 351-363.	1.9	59
225	Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney International, 2006, 69, 1081-1087.	2.6	340
226	Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study. Kidney International, 2006, 70, 192-198.	2.6	63
227	Superior dialytic clearance of $\beta_2$ -microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney International, 2006, 70, 794-799.	2.6	93
228	Drug Interaction Between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient. Transplantation, 2005, 79, 737.	0.5	21
229	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney International, 2005, 67, 2477-2487.	2.6	108
230	In vivo evaluation of a colonic delivery system using isotope techniques. Alimentary Pharmacology and Therapeutics, 2005, 21, 187-194.	1.9	16
231	Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. American Journal of Kidney Diseases, 2005, 45, e33-e37.	2.1	30
232	Time Profiles of Peritoneal and Renal Clearances of Different Uremic Solutes in Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2005, 46, 512-519.	2.1	77
233	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 1997-2004.	2.6	157
234	The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transplantation, 2005, 11, 853-854.	1.3	10

#	ARTICLE	IF	CITATIONS
235	Gas Chromatographic-Mass Spectrometric Analysis for Measurement of p-Cresol and Its Conjugated Metabolites in Uremic and Normal Serum. <i>Clinical Chemistry</i> , 2005, 51, 1535-1538.	1.5	172
236	A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 391-394.	1.3	8
237	Detoxifying Capacity and Kinetics of Prometheus <sup>®</sup> - A New Extracorporeal System for the Treatment of Liver Failure. <i>Blood Purification</i> , 2005, 23, 349-358.	0.9	82
238	A Prospective, Randomized, Double-Blind Crossover Study on the Use of 5% Citrate Lock versus 10% Citrate Lock in Permanent Hemodialysis Catheters. <i>Blood Purification</i> , 2005, 23, 101-105.	0.9	27
239	Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1714-1720.	0.4	123
240	Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2840-2842.	0.3	10
241	Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 1536-1543.	2.2	62
242	Heparin-Coated Hemodialyzers - The Holy Grail for Patients at Risk of Bleeding?. <i>Nephron Clinical Practice</i> , 2004, 97, c1-c2.	2.3	1
243	Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 469-473.	0.4	69
244	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1281-1287.	0.4	273
245	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1895-1901.	0.4	83
246	The value of tuberculin skin testing in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 433-438.	0.4	54
247	Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. <i>Kidney International</i> , 2004, 65, 1842-1849.	2.6	206
248	Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. <i>American Journal of Kidney Diseases</i> , 2004, 44, 278-285.	2.1	155
249	Acute toxic renal failure. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2004, 18, 37-52.	1.7	52
250	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1421-1425.	1.7	28
251	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 434-447.	2.3	157
252	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. <i>Clinical Pharmacokinetics</i> , 2004, 43, 741-762.	1.6	102

#	ARTICLE	IF	CITATIONS
253	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. <i>New England Journal of Medicine</i> , 2004, 350, 1516-1525.	13.9	1,023
254	189 Improvement in systemic hemodynamics after mars is associated with a decrease in vasoactive substances in patients with acute on chronic liver failure (AOCLF): Results of a randomised trial. <i>Journal of Hepatology</i> , 2004, 40, 61-62.	1.8	1
255	Validation of a New Test Meal for a Protein Digestion Breath Test in Humans. <i>Journal of Nutrition</i> , 2004, 134, 806-810.	1.3	21
256	Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. <i>Clinical Transplantation</i> , 2003, 17, 171-176.	0.8	12
257	The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. <i>Clinical Transplantation</i> , 2003, 17, 234-241.	0.8	54
258	Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. <i>Kidney International</i> , 2003, 64, 2238-2243.	2.6	178
259	Evidence for impaired assimilation of protein in chronic renal failure. <i>Kidney International</i> , 2003, 64, 2196-2203.	2.6	107
260	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 866-880.	1.0	99
261	A young patient with unexplained acute hepatorenal dysfunction. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1220-1222.	0.4	4
262	13C-breath tests in peritoneal dialysis patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 931-932.	0.8	3
263	Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 447-451.	1.0	20
264	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. <i>Transplantation</i> , 2003, 75, 665-672.	0.5	142
265	C3D DEPOSITION IN PERITUBULAR CAPILLARIES INDICATES A VARIANT OF ACUTE RENAL ALLOGRAFT REJECTION CHARACTERIZED BY A WORSE CLINICAL OUTCOME. <i>Transplantation</i> , 2003, 76, 102-108.	0.5	47
266	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. <i>Blood Purification</i> , 2003, 21, 244-252.	0.9	44
267	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 923-926.	0.4	38
268	role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1164-1170.	0.3	18
269	Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2002, 2, 989-992.	2.6	58
270	Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. <i>American Journal of Kidney Diseases</i> , 2002, 39, 315-323.	2.1	60

#	ARTICLE	IF	CITATIONS
271	Magnesium chloride slows gastric emptying, but does not affect digestive functions. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1571-1577.	1.9	6
272	Gastric emptying in renal failure patients using the <sup>13</sup> C-octanoic acid breath test: facts and artifacts. <i>Peritoneal Dialysis International</i> , 2002, 22, 732-3; author reply 734-5.	1.1	0
273	“Full house” positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2258-2262.	0.4	25
274	Alteration in digestion and absorption of nutrients during profound acid suppression. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2001, 15, 539-551.	1.0	26
275	THE EFFECT OF MYCOPHENOLATE MOFETIL ON HEPATITIS B VIRAL LOAD IN STABLE RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS B. <i>Transplantation</i> , 2001, 72, 1165-1166.	0.5	15
276	Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. <i>Transplantation</i> 2001; 72: 1655.. <i>Transplantation</i> , 2001, 72, 1593-1594.	0.5	4
277	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. <i>Transplantation</i> , 2001, 72, 1655-1661.	0.5	128
278	A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. <i>International Journal of Artificial Organs</i> , 2001, 24, 208-11.	0.7	17
279	Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. <i>Acta Oto-rhino-laryngologica Belgica</i> , 2001, 55, 177-86.	0.0	6
280	Death with functioning graft—a preventable cause of graft loss. <i>Annals of Transplantation</i> , 2001, 6, 17-20.	0.5	7
281	Dialysis Techniques in the Critic Ally-Ill Patient. <i>Acta Clinica Belgica</i> , 2000, 55, 237-243.	0.5	0
282	<sup>13</sup> C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine. <i>Gut</i> , 2000, 46, 52-57.	6.1	27
283	Amount and fate of egg protein escaping assimilation in the small intestine of humans. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G935-G943.	1.6	85
284	Gastric emptying in hyperemesis gravidarum and non-dyspeptic pregnancy. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 237-243.	1.9	88
285	Determination of Deuterated Phenylalanine and Tyrosine in Egg Protein by GCQ. <i>Journal of High Resolution Chromatography</i> , 1999, 22, 465-468.	2.0	2
286	Validation of the lactose-[ <sup>13</sup> C]ureide breath test for determination of orocecal transit time by scintigraphy. <i>Journal of Nuclear Medicine</i> , 1999, 40, 1451-5.	2.8	57
287	Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 1011-1019.	1.9	74
288	Digestibility of Cooked and Raw Egg Protein in Humans as Assessed by Stable Isotope Techniques. <i>Journal of Nutrition</i> , 1998, 128, 1716-1722.	1.3	116

#	ARTICLE	IF	CITATIONS
289	Study of protein assimilation, using stable isotope techniques. Revista De Medicina De La Universidad De Navarra, 1998, 42, 104-8.	0.0	1
290	Production of Egg Proteins, Enriched with L-Leucine-13C1, for the Study of Protein Assimilation in Humans Using the Breath Test Technique ., Journal of Nutrition, 1997, 127, 327-331.	1.3	38
291	Influence of dietary protein supplements on the formation of bacterial metabolites in the colon.. Gut, 1997, 41, 70-76.	6.1	200
292	Evaluation of the role of gastric digestion in overall protein assimilation by a combined13C-egg white -14C-octanoic acid breath test. European Journal of Nutrition, 1997, 36, 374-374.	4.6	0